The new technology can monitor interactions between individual cells in real time

According to the organization of American physicists on July 18 (Beijing time), scientists in the United States have developed a new technology, the nano sensor "stick" on the surface of cell membrane, can do real-time monitoring of cell interaction, far more clear than before. The innovative technology will allow scientists to better understand complex cell biology, monitor the growth of transplanted cells and develop effective treatments for diseases. The latest research is published in the July 17 issue of the journal Nature Nanotechnology.

In the study, the scientists used nanotechnology to "anchor" a sensor to the cell membrane of a single cell, allowing them to accurately and in real time monitor the signal transduction of the cell in the microenvironment and the transplanted cell or tissue. Previous cell signaling sensors could only measure the overall activity of one group of cells. The new technology allows them to monitor interactions between individual cells in real time with unprecedented spatial and temporal clarity, said Jeffrey karp, director of the regenerative treatment center at brigham and women's hospital in Boston. Better insights into the details of cell signaling and interactions between cells and drugs are important for basic medicine and drug development.

The method could be refined into a tool for studying the interactions between medicine and cells on a regular basis, and could also be used in the future of personalized medicine, the scientists said. "In the future, medical experts will be able to use this technique to test the effects of a drug on cells and cell interactions before developing appropriate treatments for patients," karp said.

Scientists are particularly excited about new technology that can track and monitor the "living" environment of transplanted cells in real time, something previously impossible. "This latest study is a major step forward toward the goal of detecting cellular interactions in real time and in high resolution, with profound implications for drug development and diagnosis," said ulrich Adrian, an immunologist at harvard medical school in Boston, Massachusetts, who was not involved in the trial.
Related News